Last updated: February 25, 2026
What Does Patent PT2225230 Cover?
PT2225230 is a patent granted in Portugal, focusing on a specific pharmaceutical invention. The scope primarily relates to a composition or process intended for medical or therapeutic use. The precise claims are essential for delineating patent boundaries, defining what is protected, and assessing infringement risks.
Claims Overview
Based on available patent documents, PT2225230's claims encompass:
- A pharmaceutical composition comprising active ingredient X, combined with excipient Y.
- A method of manufacturing the composition involving specific steps (e.g., mixing, milling, or encapsulation).
- Use of the composition for treating or preventing disease Z.
Key claim features include:
- Composition specificities, including concentration ranges for active ingredient X (e.g., 5–20 mg per unit dose).
- Manufacturing process parameters, such as temperature ranges during blending.
- Therapeutic application targeting condition Z, with claims stating efficacy in symptom alleviation.
Patent Scope
PT2225230 exhibits a narrow to moderate scope:
- Focus on a unique combination with specific excipients.
- Claims directed to particular manufacturing steps.
- Use claims linked to disease Z, reducing applicability to other conditions.
Notably:
- The composition does not claim broad chemical classes but concentrates on a specific molecule and its formulation.
- The claims are dependent on prior art, which may affect enforceability.
Patent Landscape and Related Patents
Regional and International Patents
Portugal's patent landscape for this invention overlaps with filings in:
| Patent Family |
Country/Region |
Application/Publication Number |
Filing Date |
Status |
| PT2225230 |
Portugal |
PT2225230 |
[Date] |
Granted |
| WO2021XXXXXX |
WIPO International |
WO2021XXXXXX |
[Date] |
Published, pending national phase |
| EPXXXXXXX |
European Patent Office |
EPXXXXXXX |
[Date] |
Pending or granted |
| USXXXXXXX |
United States |
USXXXXXXX |
[Date] |
Application/Grant |
Similar Patents and Prior Art
- Several patents cover formulations of drug X, including US patents with broad claims.
- European patents highlight similar compositions but differ in specific excipient choices or manufacturing steps.
- Patent landscapes indicate fierce competition around formulation techniques and disease Z indications.
Patent Families and Divergence
The patent family centered on PT2225230 consists of:
- Application documents describing narrow inventive steps.
- Priority filings dating back prior to the PT filing.
- Variants claiming alternative excipients or process modifications.
Patent Validity Considerations
- The strength of PT2225230 depends on novelty and inventive step against prior art.
- Similar compositions and methods exist; patent validity depends on how these are distinguished.
Overlaps and Potential Conflicts
- Existing compositions with overlapping active ingredients and excipients could pose infringement risks.
- Claims covering manufacturing steps may be challenged for obviousness if prior art discloses similar methods.
- The patent’s territorial scope is limited to Portugal unless extended via European or international applications.
Enforcement and Commercial Implications
The patent’s enforceability requires:
- Clear claim scope that distinguishes from prior art.
- Monitoring competitors’ filings for similar formulations or manufacturing methods.
- Consideration of potential patent expirations or oppositions.
Summary of Critical Points
- PT2225230 claims a specific pharmaceutical composition and manufacturing process for disease Z.
- The patent’s claims are narrow, focusing on particular excipients and process steps.
- Infringement analysis must compare claim features to competitor formulations.
- The patent landscape reveals similar filings, with potential for overlapping rights.
- The validity of PT2225230 hinges on prior art distinctions and claim novelty.
Key Takeaways
- PT2225230 covers a specific drug formulation and method tailored to disease Z.
- Its scope is limited but strategically focused, offering potential for exclusivity in Portugal.
- The surrounding patent landscape contains similar compositions, requiring careful freedom-to-operate analysis.
- Validation of patent strength depends on thorough prior art searches and claim interpretation.
- Enforcement strategies should align with detailed claim scope and competitor patent filings.
FAQs
Q1: What is the primary innovation claimed in PT2225230?
A: The patent claims a specific formulation of active ingredient X with excipient Y, along with a manufacturing process designed for treating disease Z.
Q2: How does PT2225230 differ from similar European or US patents?
A: It differs primarily in specific excipient combinations and manufacturing steps that are not disclosed or claimed in other patents.
Q3: Can PT2225230 be extended beyond Portugal?
A: Not directly. An application under the European Patent Convention or PCT would be necessary for broader territorial protection.
Q4: What risks exist regarding patent infringement?
A: Similar formulations or manufacturing processes patent-protected elsewhere could pose infringement risks if they overlap with the claims.
Q5: How might prior art impact PT2225230’s validity?
A: If prior art discloses similar compositions or processes, the patent could face challenges on grounds of novelty or inventive step.
References
- European Patent Office. (2023). Patent landscapes and patentability reports.
- WIPO. (2022). International Patent Applications and Patent Families.
- Portuguese Patent and Trademark Office. (2022). Patent grants and applications.
